TREATMENTS FOR EGFR MUTATION-POSITIVE (M plus ) NSCLC PATIENTS - A NETWORK META-ANALYSIS (NMA) BY MUTATION TYPE

被引：6
|
作者：
Popat, S. [1 ]
Yang, J. C. H. [2 ]
Lungershausen, J. [3 ]
Griebsch, I [3 ]
Marten, A. [4 ]
Wu, Y. L. [5 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Natl Taiwan Univ, Taipei 10764, Taiwan
[3] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2166
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A615 / A615
页数：1
相关论文
共 50 条
  • [21] Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC
    Koyama, Kenichi
    Miura, Satoru
    Watanabe, Satoshi
    Shoji, Satoshi
    Koshio, Jun
    Hayashi, Yoshiki
    Ishikawa, Daisuke
    Sato, Ko
    Miyabayashi, Takao
    Okajima, Masaaki
    Ota, Takeshi
    Tanaka, Tomohiro
    Matsumoto, Naoya
    Kuriyama, Hideyuki
    Abe, Tetsuya
    Nozaki, Koichiro
    Ichikawa, Kosuke
    Kondo, Rie
    Tanaka, Hiroshi
    Kikuchi, Toshiaki
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Outcomes of NSCLC patients with positive EGFR mutation
    Diver, Sarah
    Haris, Mohammed
    Khan, Shahul Leyakathali
    Kerr, Jane
    Edwards, Jane
    Munavvar, Mohammed
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [23] Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC
    Hamaguchi, Reo
    Okamoto, Toshihiro
    Sato, Masaaki
    Hasegawa, Michiko
    Wada, Hiromi
    ANTICANCER RESEARCH, 2017, 37 (09) : 5141 - 5145
  • [24] Analysis of 148 cases of EGFR mutation-positive lung cancer patients
    Abe, Yuko
    Tanio, Yoshiro
    Shirai, Yuya
    Mitui, Yuichi
    Ogawa, Koichi
    Akazawa, Yuki
    Ueno, Kiyonobu
    Oomori, Kenichi
    Shimamoto, Shigetoshi
    Fushimi, Hiroaki
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm plus ) NSCLC: Analysis of Time on Treatment and OS
    Park, K.
    Tan, E.
    O'Byrne, K.
    Zhang, L.
    Boyer, M.
    Mok, T.
    Hirsh, V.
    Yang, J. C.
    Schuler, M.
    Yamamoto, N.
    Sequist, L.
    Wu, Y.
    Zhou, C.
    Ehrnrooth, E.
    Marten, A.
    Tang, W.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2215 - S2216
  • [26] Afatinib in Patients with Advanced HER2 Mutation-Positive (M plus ) NSCLC Previously Treated with Chemotherapy
    Zhou, Caicun
    Fan, Yun
    Wang, Huijuan
    Liam, Chong Kin
    Hu, Chengjie
    Cseh, Agnieszka
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1077 - S1077
  • [27] Comparison of Maintenance Therapy in EGFR Mutation Negative and EGFR Mutation Positive NSCLC Patients
    Joshi, Amit
    Noronha, Vanita
    Mahajan, Abhishek
    Janu, Amit
    Chougule, Anuradha
    Jambhekar, Nirmala
    Kumar, Rajeev
    Prabhash, Kumar
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S763 - S763
  • [28] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [29] Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
    Liu, Rong
    Zhou, Jianying
    Ling, Xia
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
  • [30] Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs
    Liao, B-C.
    Bai, Y-Y.
    Lin, C-C.
    Lin, S-Y.
    Lee, Y-F.
    Ho, C-C.
    Shih, J-Y.
    Chang, Y-C.
    Yu, C-J.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S123 - S124
12345